RNS | 29 NOVEMBER 2021
ImmuPharma PLC
("ImmuPharma" or the "Company")
COLLABORATION WITH IMPERIAL COLLEGE LONDON
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company,
is very pleased to announce that it has signed a 2-year collaboration agreement with Imperial College London.
Under the collaboration, Imperial College will provide significant intellectual input and guidance on a number of innovative peptide assets being developed at our R&D subsidiary, ImmuPharma Biotech in Bordeaux.
Dr Tim Franklin, Chief Operating Officer of ImmuPharma, added: "We are all extremely excited to be working with such a world leading academic institute. This union will be invaluable in guiding and progressing our earlier stage product development portfolio, as well as enhancing our intellectual property base."
Dr Sébastien Goudreau, Chief Executive Officer of ImmuPharma Biotech, added: "We are delighted that now with the full support from the new Board for our innovative research programs, we have the opportunity of working with collaboration partners which include world leading academic institutes such as Imperial College London."
End
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
| For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US. The Lupzor™ Phase 3 trial is on track to commence in 2022.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
About Imperial College London
Imperial College is a global top ten university with a world-class reputation in science, engineering, business and medicine. For more information go to: https://www.imperial.ac.uk
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
